191744-13-5

Basic information

• Product Name: CX614
• Synonyms: CX614;BDP 37;LiD 37;2,3,6a,7,8,9-Hexahydro-11H-1,4-dioxino[2,3-g]pyrrolo[2,1-b][1,3]benzoxazin-11-one;6a,7,8,9-tetrahydro-2H-[1,4]dioxino[2',3':4,5]benzo[1,2-e]pyrrolo[2,1-b][1,3]oxa;6a,7,8,9-Tetrahydro-2H-[1,4]dioxino[2',3':4,5]benzo[1,2-e]pyrrolo[2,1-b][1,3]oxazin-11(3H)-one
• CAS NO: 191744-13-5
• Molecular Formula: C13H13NO4
• Molecular Weight: 247.249
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 191744-13-5.mol
• Article Data: 2

Chemical Properties

• Melting Point: 149-151°C
• Boiling Point: 473.8 °C at 760 mmHg
• Flash Point: 240.3 °C
• Appearance: /
• Density: 1.45 g/cm³
• Vapor Pressure: 3.82E-09mmHg at 25°C
• Refractive Index: 1.651
• Storage Temp.: Refrigerator
• Solubility: Chloroform, DMSO, Methanol
• PKA: -1.49±0.20(Predicted)
• CAS DataBase Reference: CX614(CAS DataBase Reference)
• NIST Chemistry Reference: CX614(191744-13-5)
• EPA Substance Registry System: CX614(191744-13-5)

Safety Data

• Hazardous Substances Data: 191744-13-5(Hazardous Substances Data)

Usage

Description

CX614 is a compound belonging to a series of AMPA modulators, specifically designed to target and modulate the activity of metabotropic AMPA receptors. It is a white to off-white solid, which indicates its solid-state chemical properties.

Uses

Used in Pharmaceutical Industry:
CX614 is used as a modulator for metabotropic AMPA receptors, which play a crucial role in various neurological processes and conditions. Its application in this industry is primarily for the development of potential therapeutic agents that can modulate the activity of these receptors, thereby providing treatment options for a range of neurological disorders.
Used in Research Applications:
In the field of scientific research, CX614 is used as a research tool to study the function and role of metabotropic AMPA receptors in cellular processes and neurological conditions. Its ability to modulate these receptors makes it a valuable compound for understanding the underlying mechanisms and pathways involved in various diseases and disorders.
Used in Drug Development:
CX614 is used as a lead compound in the development of new drugs targeting metabotropic AMPA receptors. Its chemical properties and receptor specificity make it a promising candidate for further optimization and modification to improve its efficacy, selectivity, and safety profile for potential therapeutic applications.

InChI:InChI=1/C13H13NO4/c15-13-8-6-10-11(17-5-4-16-10)7-9(8)18-12-2-1-3-14(12)13/h6-7,12H,1-5H2

Upstream product

• 1602983-08-3 (7-hydroxy-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)(pyrrolidin-1-yl)methanone 
• 1602983-06-1 pyrrolidin-1-yl(2,4,5-trihydroxyphenyl)methanone 
• 695197-84-3 pyrrolidin-1-yl(2,4,5-trimethoxyphenyl)methanone 
• 42833-66-9 2,4,5-trimethoxybenzoyl chloride 
• 490-64-2 asaronic acid 
• 116757-65-4 7-hydroxy-2,3-dihydrobenzo[b][1,4]dioxine-6-carbaldehyde 
• 1268833-96-0 7-hydroxy-2,3-dihydrobenzo[b][1,4]dioxine-6-carbonitrile 
• 201230-82-2 carbon monoxide 
• 1268833-83-5 7-(5,6-dihydro-4H-1,3-oxazin-2-yl)-2,3-dihydrobenzo[b][1,4]dioxin-6-ol 

Relevant articles and documents

Predictably selective (sp3)C-O bond formation through copper catalyzed dehydrogenative coupling: Facile synthesis of dihydro-oxazinone derivatives

An intramolecular dehydrogenative (sp3)C-O bond formation in salicylamides can be initiated by an active Cu/O2 species to generate pharamaceutically relevant dihydro-oxazinones. Experimental findings suggest that stereoelectronic parameters in both coupling partners are controlling factors for site selectivity in bond formation. Mechanistic investigations including isotope labeling, kinetic studies helped to propose a catalytic cycle. The method provides a convenient synthesis of an investigational new medicine CX-614, which has potential in finding treatment for Parkinson's and Alzheimer's diseases.